SYRE (STOCKS)
Spyre Therapeutics, Inc. Common Stock
$62.290000
+11.000000 (+21.45%)
Prev close: $51.290000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Cameron Turtle
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,965.31M
- Employees
- 95
- P/E (TTM)
- -30.45
- P/B (TTM)
- 7.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.70 | $-0.79 | +0.0903 | +11.43% |
|
Sep 2025 (Q3)
|
$-0.15 | $-0.76 | +0.6113 | +80.30% |
|
Jun 2025 (Q2)
|
$-0.77 | $-0.77 | -0.0013 | -0.17% |
|
Mar 2025 (Q1)
|
$-0.60 | $-0.86 | +0.2578 | +30.05% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $54.34M |
| Operating Expenses | $209.56M |
| Operating Income/Loss | -$209.56M |
| Income/Loss From Continuing Operations After Tax | -$155.20M |
| Income/Loss From Continuing Operations Before Tax | -$155.22M |
| Income Tax Expense/Benefit | -$15.00K |
| Net Income/Loss | -$155.20M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$155.20M |
| Net Income/Loss Available To Common Stockholders, Basic | -$155.20M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $777.78M |
| Current Assets | $777.78M |
| Cash | $756.50M |
| Other Current Assets | $21.28M |
| Noncurrent Assets | $0.00 |
| Liabilities | $62.55M |
| Current Liabilities | $58.69M |
| Noncurrent Liabilities | $3.86M |
| Equity | $715.24M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $715.24M |
| Liabilities And Equity | $777.78M |
| Net Cash Flow From Operating Activities | -$169.25M |
| Net Cash Flow From Operating Activities, Continuing | -$169.25M |
| Net Cash Flow From Investing Activities | -$143.48M |
| Net Cash Flow From Investing Activities, Continuing | -$143.48M |
| Net Cash Flow From Financing Activities | $309.03M |
| Net Cash Flow From Financing Activities, Continuing | $309.03M |
| Exchange Gains/Losses | $0.00 |
| Net Cash Flow | -$3.70M |
| Net Cash Flow, Continuing | -$3.70M |
| Comprehensive Income/Loss | -$154.51M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$154.51M |
| Other Comprehensive Income/Loss | -$154.51M |